| Author | Souza, Thiago Moreno L. | |
| Author | Morel, Carlos Medicis | |
| Access date | 2020-12-15T19:41:34Z | |
| Available date | 2020-12-15T19:41:34Z | |
| Document date | 2020 | |
| Citation | SOUZA, Thiago Moreno Lopes; MOREL, Carlos Medicis. The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control. Biosafety and Health, p. 1-9, 29 Nov. 2020. | |
| ISSN | 2590-0536 | |
| URI | https://www.arca.fiocruz.br/handle/icict/44921 | |
| Language | eng | en_US |
| Publisher | Elsevier | |
| Later version | https://www.arca.fiocruz.br/handle/icict/52484 | |
| Rights | open access | |
| Subject in Portuguese | SARS-CoV-2 | pt_BR |
| Subject in Portuguese | COVID-19 | pt_BR |
| Subject in Portuguese | Instalações de biossegurança | pt_BR |
| Subject in Portuguese | Países em desenvolvimento de inovação (IDCs) | pt_BR |
| Subject in Portuguese | Vigilância metagenômica | pt_BR |
| Title | The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control | en_US |
| Type | Preprint | |
| DOI | 10.1016/j.bsheal.2020.11.007 | |
| Abstract | The 2019 coronavirus disease (COVID-19) pandemic represents an enormous challenge to all countries, regardless of their development status. The manipulation of its etiologic agent SARS-CoV-2 requires a biosafety containment level 3 laboratories (BSL-3) to understand virus biology and in vivo pathogenesis as well as the translation of new knowledge into the preclinical development of vaccines and antivirals. As such, BSL-3 facilities should be considered an integral part of any public health response to emerging infectious disease prevention, control and management. Differently from BSL2, BSL-3 units vary considerably along the range from industrialized to the least developed countries. Innovative Developing Countries (IDCs) such as Brazil, which excelled at controlling the 2015-2017 Zika epidemic, had to face a serious flaw in its disease control and prevention structure: the scarcity and uneven geographic distribution of its BSL-3 facilities, including those for preclinical animal experimentation. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil. | |
| Subject | SARS-CoV-2 | en_US |
| Subject | COVID-19 | en_US |
| Subject | Biosafety facilities | en_US |
| Subject | Innovative Developing Countries (IDCs) | en_US |
| Subject | Metagenomics surveillance | en_US |
| Peer reviewed | Não | |
| Publication status | Publicado | |
| xmlui.metadata.dc.subject.ods | 01 Erradicação da pobreza | |
| xmlui.metadata.dc.subject.ods | 09 Indústria, inovação e infraestrutura | |
